Price List Atopy - Atopy-IL-13 IL-31.xlsx
XLSX spreadsheet 46 KB Posted
- Solicitation number
- HT9402-25-Q-9301
- Issued by
-
Defense Health Agency
About this file
This is a Price List for a Department of Defense (DoD) Uniform Formulary Blanket Purchase Agreement (BPA) for pharmaceutical agents in the Atopy drug class, specifically targeting IL-13 and IL-31 subclasses. The solicitation (HT9402-25-Q-9301) is issued by the Defense Health Agency for the August 2025 Pharmacy and Therapeutics (P&T) Committee Meeting, with quotes due on June 26, 2025. The document outlines complex pricing and formulary scenarios for potential pharmaceutical agents, including provisions for Uniform Formulary (UF) placement, step therapy requirements, and retail refund structures.
Key details include potential prior authorization requirements, special reimbursement methods, and the possibility of preferential status or exclusion from the TRICARE pharmacy benefit program. The BPA includes multiple appendices covering different formulary scenarios for both Military Treatment Facilities/Mail Order and TRICARE Retail channels, with specific condition sets for one or more agents. Manufacturers are required to submit fully executed signature pages with quote information, and the pricing mechanism involves calculations based on non-Federal Average Manufacturer Price (non-FAMP) and Federal Ceiling Price (FCP) with additional offered refunds.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| Price List Diuretics - Mineralocorticoid Receptor Antagonists.xlsx | XLSX spreadsheet | |
| August 2025 PT Meeting Reporting.xlsx | XLSX spreadsheet | |
| NDC Price List FAQ Class Review.pdf | ||
| RFQ HT9402-25-Q-9301 CR.pdf |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
BPA
| UF BPA NDC Price List for the August 2025 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | August 6-7, 2025 |
| DOD Uniform Formulary Subclass: | ATOPY: IL-13, IL-31 | Quotes due: | June 26, 2025 |
| Formulary Notes |
Class Note(s): Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The DoD P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the DoD P&T Committee may identify candidates to recommend for complete exclusion from the TRICARE pharmacy benefit program.
Step Therapy Addendum: Grandfathering: a PA process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to the patient at any MTF, Retail, or Mail point of service. There will be no grandfathering between biosimilar products.
All Scenarios:
• Agents with RFQ not submitted or selected may be designated non-step preferred (i.e. after-step).
• Specialist bypass and/or drug auto-lookback may be considered for the step-preferred agent.
• The P&T Committee may consider a step preference for the Atopic Dermatitis indication, and all other indications would not have a step.
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.
Blanket Purchase Agreement Appendix – Class Review
| #1 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | ATOPY: IL-13, IL-31 | Quotes due: | June 26, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit | ||
| Scenario 1: One agent UF and before the step | ||||||||
| Scenario 1 | 254ATAIG1UFBS1 | Uniform Formulary | ||||||
| Before Step Therapy | 1 | NO QUOTE | ||||||
| 254ATAIG1UFAS1M | Uniform Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| 254ATAIG1NFAS1M | Non-Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| Scenario 2: One or more agents UF | ||||||||
| Scenario 2 | 254ATAIG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | ||||
| 254ATAIG1NF1M | Non-Formulary | 1 or more | NO QUOTE | |||||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Class Review
| #2 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | ATOPY: IL-13, IL-31 | Quotes due: | June 26, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit | ||
| Scenario 1: One agent UF and before the step | ||||||||
| Scenario 1 | 254ATAIG1UFBS1 | Uniform Formulary | ||||||
| Before Step Therapy | 1 | NO QUOTE | ||||||
| 254ATAIG1UFAS1M | Uniform Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| 254ATAIG1NFAS1M | Non-Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| Scenario 2: One or more agents UF | ||||||||
| Scenario 2 | 254ATAIG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | ||||
| 254ATAIG1NF1M | Non-Formulary | 1 or more | NO QUOTE | |||||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Class Review
| #3 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | ATOPY: IL-13, IL-31 | Quotes due: | June 26, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit | ||
| Scenario 1: One agent UF and before the step | ||||||||
| Scenario 1 | 254ATAIG1UFBS1 | Uniform Formulary | ||||||
| Before Step Therapy | 1 | NO QUOTE | ||||||
| 254ATAIG1UFAS1M | Uniform Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| 254ATAIG1NFAS1M | Non-Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| Scenario 2: One or more agents UF | ||||||||
| Scenario 2 | 254ATAIG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | ||||
| 254ATAIG1NF1M | Non-Formulary | 1 or more | NO QUOTE | |||||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Class Review
| #4 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | ATOPY: IL-13, IL-31 | Quotes due: | June 26, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit | ||
| Scenario 1: One agent UF and before the step | ||||||||
| Scenario 1 | 254ATAIG1UFBS1 | Uniform Formulary | ||||||
| Before Step Therapy | 1 | NO QUOTE | ||||||
| 254ATAIG1UFAS1M | Uniform Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| 254ATAIG1NFAS1M | Non-Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| Scenario 2: One or more agents UF | ||||||||
| Scenario 2 | 254ATAIG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | ||||
| 254ATAIG1NF1M | Non-Formulary | 1 or more | NO QUOTE | |||||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Class Review
| #5 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | August 6-7, 2025 | ||||
| DOD Uniform Formulary Subclass: | ATOPY: IL-13, IL-31 | Quotes due: | June 26, 2025 | |||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order | |||
| 1.00 | ||||||||
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit | ||
| Scenario 1: One agent UF and before the step | ||||||||
| Scenario 1 | 254ATAIG1UFBS1 | Uniform Formulary | ||||||
| Before Step Therapy | 1 | 1.00 | NO QUOTE | |||||
| 254ATAIG1UFAS1M | Uniform Formulary | |||||||
| After Step Therapy | 1 or more | 1.00 | NO QUOTE | |||||
| 254ATAIG1NFAS1M | Non-Formulary | |||||||
| After Step Therapy | 1 or more | 1.00 | NO QUOTE | |||||
| Scenario 2: One or more agents UF | ||||||||
| Scenario 2 | 254ATAIG1UF1M | Uniform Formulary | 1 or more | 1.00 | NO QUOTE | |||
| 254ATAIG1NF1M | Non-Formulary | 1 or more | 1.00 | NO QUOTE | ||||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Class Review
| #6 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | ATOPY: IL-13, IL-31 | Quotes due: | June 26, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit | ||
| Scenario 1: One agent UF and before the step | ||||||||
| Scenario 1 | 254ATAIG1UFBS1 | Uniform Formulary | ||||||
| Before Step Therapy | 1 | NO QUOTE | ||||||
| 254ATAIG1UFAS1M | Uniform Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| 254ATAIG1NFAS1M | Non-Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| Scenario 2: One or more agents UF | ||||||||
| Scenario 2 | 254ATAIG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | ||||
| 254ATAIG1NF1M | Non-Formulary | 1 or more | NO QUOTE | |||||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Class Review
| #7 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | ATOPY: IL-13, IL-31 | Quotes due: | June 26, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit | ||
| Scenario 1: One agent UF and before the step | ||||||||
| Scenario 1 | 254ATAIG1UFBS1 | Uniform Formulary | ||||||
| Before Step Therapy | 1 | NO QUOTE | ||||||
| 254ATAIG1UFAS1M | Uniform Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| 254ATAIG1NFAS1M | Non-Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| Scenario 2: One or more agents UF | ||||||||
| Scenario 2 | 254ATAIG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | ||||
| 254ATAIG1NF1M | Non-Formulary | 1 or more | NO QUOTE | |||||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Class Review
| #8 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | ATOPY: IL-13, IL-31 | Quotes due: | June 26, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit | ||
| Scenario 1: One agent UF and before the step | ||||||||
| Scenario 1 | 254ATAIG1UFBS1 | Uniform Formulary | ||||||
| Before Step Therapy | 1 | NO QUOTE | ||||||
| 254ATAIG1UFAS1M | Uniform Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| 254ATAIG1NFAS1M | Non-Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| Scenario 2: One or more agents UF | ||||||||
| Scenario 2 | 254ATAIG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | ||||
| 254ATAIG1NF1M | Non-Formulary | 1 or more | NO QUOTE | |||||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Class Review
| #9 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | ATOPY: IL-13, IL-31 | Quotes due: | June 26, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit | ||
| Scenario 1: One agent UF and before the step | ||||||||
| Scenario 1 | 254ATAIG1UFBS1 | Uniform Formulary | ||||||
| Before Step Therapy | 1 | NO QUOTE | ||||||
| 254ATAIG1UFAS1M | Uniform Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| 254ATAIG1NFAS1M | Non-Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| Scenario 2: One or more agents UF | ||||||||
| Scenario 2 | 254ATAIG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | ||||
| 254ATAIG1NF1M | Non-Formulary | 1 or more | NO QUOTE | |||||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Class Review
| #10 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | ATOPY: IL-13, IL-31 | Quotes due: | June 26, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit | ||
| Scenario 1: One agent UF and before the step | ||||||||
| Scenario 1 | 254ATAIG1UFBS1 | Uniform Formulary | ||||||
| Before Step Therapy | 1 | NO QUOTE | ||||||
| 254ATAIG1UFAS1M | Uniform Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| 254ATAIG1NFAS1M | Non-Formulary | |||||||
| After Step Therapy | 1 or more | NO QUOTE | ||||||
| Scenario 2: One or more agents UF | ||||||||
| Scenario 2 | 254ATAIG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | ||||
| 254ATAIG1NF1M | Non-Formulary | 1 or more | NO QUOTE | |||||
| If cell highlights red, please confirm intent not to submit a quote |
ADP (non-FAMP Discount)
| UF ADP Appendix for the August 2025 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | August 6-7, 2025 |
| DOD Uniform Formulary Subclass: | ATOPY: IL-13, IL-31 | Quotes due: | June 26, 2025 |
| Formulary Notes |
Class Note(s): Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The DoD P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the DoD P&T Committee may identify candidates to recommend for complete exclusion from the TRICARE pharmacy benefit program.
Step Therapy Addendum: Grandfathering: a PA process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to the patient at any MTF, Retail, or Mail point of service. There will be no grandfathering between biosimilar products.
All Scenarios:
• Agents with RFQ not submitted or selected may be designated non-step preferred (i.e. after-step).
• Specialist bypass and/or drug auto-lookback may be considered for the step-preferred agent.
• The P&T Committee may consider a step preference for the Atopic Dermatitis indication, and all other indications would not have a step.
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.
Additional Discount Program Appendix – Class Review
| #1 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | ATOPY: IL-13, IL-31 | Quotes due: | June 26, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* | ||
| Scenario 1: One agent T2 and before the step | ||||||||||
| Scenario 1 | 254ATAIG1T2BS1 | Tier 2 | ||||||||
| Before Step Therapy | 1 | |||||||||
| 254ATAIG1T2AS1M | Tier 2 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| 254ATAIG1T3AS1M | Tier 3 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| Scenario 2: One or more agents T2 | ||||||||||
| Scenario 2 | 254ATAIG1T21M | Tier 2 | 1 or more | |||||||
| 254ATAIG1T31M | Tier 3 | 1 or more | ||||||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Class Review
| #2 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | ATOPY: IL-13, IL-31 | Quotes due: | June 26, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* | ||
| Scenario 1: One agent T2 and before the step | ||||||||||
| Scenario 1 | 254ATAIG1T2BS1 | Tier 2 | ||||||||
| Before Step Therapy | 1 | |||||||||
| 254ATAIG1T2AS1M | Tier 2 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| 254ATAIG1T3AS1M | Tier 3 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| Scenario 2: One or more agents T2 | ||||||||||
| Scenario 2 | 254ATAIG1T21M | Tier 2 | 1 or more | |||||||
| 254ATAIG1T31M | Tier 3 | 1 or more | ||||||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Class Review
| #3 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | ATOPY: IL-13, IL-31 | Quotes due: | June 26, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* | ||
| Scenario 1: One agent T2 and before the step | ||||||||||
| Scenario 1 | 254ATAIG1T2BS1 | Tier 2 | ||||||||
| Before Step Therapy | 1 | |||||||||
| 254ATAIG1T2AS1M | Tier 2 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| 254ATAIG1T3AS1M | Tier 3 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| Scenario 2: One or more agents T2 | ||||||||||
| Scenario 2 | 254ATAIG1T21M | Tier 2 | 1 or more | |||||||
| 254ATAIG1T31M | Tier 3 | 1 or more | ||||||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Class Review
| #4 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | ATOPY: IL-13, IL-31 | Quotes due: | June 26, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* | ||
| Scenario 1: One agent T2 and before the step | ||||||||||
| Scenario 1 | 254ATAIG1T2BS1 | Tier 2 | ||||||||
| Before Step Therapy | 1 | |||||||||
| 254ATAIG1T2AS1M | Tier 2 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| 254ATAIG1T3AS1M | Tier 3 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| Scenario 2: One or more agents T2 | ||||||||||
| Scenario 2 | 254ATAIG1T21M | Tier 2 | 1 or more | |||||||
| 254ATAIG1T31M | Tier 3 | 1 or more | ||||||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Class Review
| #5 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | ATOPY: IL-13, IL-31 | Quotes due: | June 26, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* | ||
| Scenario 1: One agent T2 and before the step | ||||||||||
| Scenario 1 | 254ATAIG1T2BS1 | Tier 2 | ||||||||
| Before Step Therapy | 1 | |||||||||
| 254ATAIG1T2AS1M | Tier 2 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| 254ATAIG1T3AS1M | Tier 3 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| Scenario 2: One or more agents T2 | ||||||||||
| Scenario 2 | 254ATAIG1T21M | Tier 2 | 1 or more | |||||||
| 254ATAIG1T31M | Tier 3 | 1 or more | ||||||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Class Review
| #6 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | ATOPY: IL-13, IL-31 | Quotes due: | June 26, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* | ||
| Scenario 1: One agent T2 and before the step | ||||||||||
| Scenario 1 | 254ATAIG1T2BS1 | Tier 2 | ||||||||
| Before Step Therapy | 1 | |||||||||
| 254ATAIG1T2AS1M | Tier 2 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| 254ATAIG1T3AS1M | Tier 3 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| Scenario 2: One or more agents T2 | ||||||||||
| Scenario 2 | 254ATAIG1T21M | Tier 2 | 1 or more | |||||||
| 254ATAIG1T31M | Tier 3 | 1 or more | ||||||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Class Review
| #7 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | ATOPY: IL-13, IL-31 | Quotes due: | June 26, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* | ||
| Scenario 1: One agent T2 and before the step | ||||||||||
| Scenario 1 | 254ATAIG1T2BS1 | Tier 2 | ||||||||
| Before Step Therapy | 1 | |||||||||
| 254ATAIG1T2AS1M | Tier 2 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| 254ATAIG1T3AS1M | Tier 3 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| Scenario 2: One or more agents T2 | ||||||||||
| Scenario 2 | 254ATAIG1T21M | Tier 2 | 1 or more | |||||||
| 254ATAIG1T31M | Tier 3 | 1 or more | ||||||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Class Review
| #8 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | ATOPY: IL-13, IL-31 | Quotes due: | June 26, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* | ||
| Scenario 1: One agent T2 and before the step | ||||||||||
| Scenario 1 | 254ATAIG1T2BS1 | Tier 2 | ||||||||
| Before Step Therapy | 1 | |||||||||
| 254ATAIG1T2AS1M | Tier 2 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| 254ATAIG1T3AS1M | Tier 3 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| Scenario 2: One or more agents T2 | ||||||||||
| Scenario 2 | 254ATAIG1T21M | Tier 2 | 1 or more | |||||||
| 254ATAIG1T31M | Tier 3 | 1 or more | ||||||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Class Review
| #9 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | ATOPY: IL-13, IL-31 | Quotes due: | June 26, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* | ||
| Scenario 1: One agent T2 and before the step | ||||||||||
| Scenario 1 | 254ATAIG1T2BS1 | Tier 2 | ||||||||
| Before Step Therapy | 1 | |||||||||
| 254ATAIG1T2AS1M | Tier 2 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| 254ATAIG1T3AS1M | Tier 3 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| Scenario 2: One or more agents T2 | ||||||||||
| Scenario 2 | 254ATAIG1T21M | Tier 2 | 1 or more | |||||||
| 254ATAIG1T31M | Tier 3 | 1 or more | ||||||||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Class Review
| #10 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | ATOPY: IL-13, IL-31 | Quotes due: | June 26, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Branded Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* | ||
| Scenario 1: One agent T2 and before the step | ||||||||||
| Scenario 1 | 254ATAIG1T2BS1 | Tier 2 | ||||||||
| Before Step Therapy | 1 | |||||||||
| 254ATAIG1T2AS1M | Tier 2 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| 254ATAIG1T3AS1M | Tier 3 | |||||||||
| After Step Therapy | 1 or more | |||||||||
| Scenario 2: One or more agents T2 | ||||||||||
| Scenario 2 | 254ATAIG1T21M | Tier 2 | 1 or more | |||||||
| 254ATAIG1T31M | Tier 3 | 1 or more | ||||||||
| If cell highlights red, please confirm intent not to submit a quote |
File details come from the government source that posted it. Updated .